Renasant Bio, Inc.
Last verified 2026-05-08. JSON
| Total raised | $30.0M |
|---|---|
| Latest round | Funding round, $30.0M, 2025-07-14 |
| Founded | unknown |
| Headquarters | BERKELEY, CA |
| Industry | bio |
| Stage | unknown |
| Website | renasantbio.com |
Renasant Bio develops small-molecule correctors and potentiators that restore polycystin proteins damaged in autosomal dominant polycystic kidney disease. It targets the roughly 12 million people with ADPKD, a genetic cause of kidney failure. Its molecules work across a broad range of mutations, none affecting more than about 2% of patients.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-14 | Funding round | $30.0M | undisclosed |
Detected tech stack
Google Cloud CDN, Sentry, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $30.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $30.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | renasantbio.com, read 2026-05-08 |
| Description | self-reported | renasantbio.com, read 2026-05-08 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $30.0M, 2025-07-14 → Funding round, $30.0M, 2025-07-14, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $30.0M, 2025-07-14 → Funding round, $30.0M, 2025-07-14 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes